Literature DB >> 6697328

Pharmacokinetic studies of anticancer drugs in tumor-bearing animals.

M G Donelli, M D'Incalci, S Garattini.   

Abstract

The pharmacokinetics of antitumor agents is a relatively recent area of research, as lack of proper specific methodology for monitoring drug levels has always hampered major efforts. Although the relationship among administered dose, tissue concentration, and therapeutic and/or toxic effects remains extremely complex, a series of experimental and clinical studies provides information on the pharmacokinetic behavior of most anticancer agents in different conditions. This review article describes examples selected from the work of this Institute on several points which may be relevant to the use of these compounds: (a) factors influencing pharmacokinetics, such as genetic constitution of the host, presence of the tumor, dose, route of administration and schedule, organ insufficiency, and interactions with other drugs; (b) drug distribution in host tissues in relation to toxic effects; (c) drug distribution to secondary tumors (metastases); (d) importance of active metabolites; and (e) drug distribution and binding to intracellular target sites. An analysis of these factors shows that many aspects are still very poorly understood and require considerable further study.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6697328

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  12 in total

1.  Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion.

Authors:  F Figoli; M L Zanette; U Tirelli; R Sorio; C Lestuzzi; R Urso; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 2.  Perspectives in the treatment of cancer metastasis.

Authors:  S Garattini
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

Review 3.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  The comparative disposition of [14C]-fotemustine in non-tumourous and tumourous mice.

Authors:  R M Ings; M Breen; K Devereux; A J Gray; F E Edwards; C Lucas; M Briggs; B V Robinson; D B Campbell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 5.  Predictive testing in cancer chemotherapy. I. In vivo.

Authors:  P H Slee; A T Van Oosterom; E A De Bruijn
Journal:  Pharm Weekbl Sci       Date:  1985-06-21

Review 6.  Predictive testing in cancer chemotherapy. II. In vitro.

Authors:  P H Slee; A T Van Oosterom; E A De Bruijn
Journal:  Pharm Weekbl Sci       Date:  1985-08-23

7.  Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model.

Authors:  P M Loadman; M C Bibby; J A Double; R S McElhinney
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

8.  Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma.

Authors:  A Guaitani; M Corada; C Lucas; A Lemoine; S Garattini; I Bartosek
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.

Authors:  G J Peters; J Lankelma; R M Kok; P Noordhuis; C J van Groeningen; C L van der Wilt; S Meyer; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Molecular cloning of the cDNA coding for mouse aldehyde oxidase: tissue distribution and regulation in vivo by testosterone.

Authors:  M Kurosaki; S Demontis; M M Barzago; E Garattini; M Terao
Journal:  Biochem J       Date:  1999-07-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.